Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.92Last Year’s EPS
-0.62Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -3.37%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall. Xenon Pharmaceuticals demonstrated significant progress in its clinical development programs, including plans to expand azetukalner into new indications such as bipolar depression. The company is also in a strong financial position to support its pipeline and strategic goals. However, challenges in enrolling patients for the PGTC study and the announced departure of CFO Sherry Aulin were noted.Company Guidance
During the Xenon Pharmaceuticals Q4 2024 earnings call, the company provided detailed guidance for the upcoming year. They anticipate a top-line data readout for their first Phase 3 epilepsy study in the second half of 2025. Xenon expects to file a New Drug Application (NDA) based on this data. The company outlined strategic priorities, including broadening the indication of their lead asset azetukalner in epilepsy and neuropsychiatric disorders such as bipolar depression, with plans to initiate a registrational program mid-year. They disclosed preclinical advancements in their Kv7 and Nav1.7 programs, aiming for multiple regulatory filings in 2025. Xenon also projects having sufficient cash reserves to fund operations into 2027, underscoring strong fiscal management.Progress in Clinical Development Programs
Xenon Pharmaceuticals made significant advancements in its clinical development programs, including the Phase 3 epilepsy program and the launch of a Phase 3 MDD program. The company plans to initiate a registrational program for azetukalner in bipolar depression.
Strong Financial Position
Xenon reported cash and cash equivalents and marketable securities of $754.4 million, anticipating having sufficient cash to fund operations into 2027.
Promising Results from Azetukalner Studies
Azutukalner showed sustained monthly reduction in seizure frequency of approximately 85% at month 36 in epilepsy patients, with impressive seizure freedom rates.
Expansion into Bipolar Depression
Plans to initiate a registrational program studying the use of azetukalner in bipolar depression based on strong scientific rationale and market research.
Positive Market Research Feedback
Market research with prescribing psychiatrists showed interest in azetukalner’s profile for bipolar depression, considering its safety profile, novel mechanism of action, and potential benefits on anhedonia.
---
XENE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XENE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $38.31 | $37.02 | -3.37% |
| Nov 12, 2024 | $43.39 | $41.97 | -3.27% |
| Aug 08, 2024 | $41.01 | $39.70 | -3.19% |
| May 09, 2024 | $42.49 | $40.54 | -4.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Xenon (XENE) report earnings?
Xenon (XENE) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Xenon (XENE) earnings time?
Xenon (XENE) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XENE EPS forecast?
XENE EPS forecast for the fiscal quarter 2025 (Q1) is -0.92.
---